Dyne Therapeutics has patented a complex involving a muscle-targeting agent linked to a molecular payload that inhibits DUX4 expression. The patent includes an anti-TfR antibody covalently linked to oligonucleotides, targeting muscle cells. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Muscle-targeting complex inhibiting dux4 expression with oligonucleotide payload
See Also:
A recently granted patent (Publication Number: US11844843B2) discloses a complex comprising an anti-transferrin receptor (TfR) antibody covalently linked to at least one oligonucleotide. The antibody includes a heavy chain with specific amino acid sequences and a light chain with a human kappa light chain constant region. The oligonucleotide is covalently linked to a lysine residue of the anti-TfR antibody, which can be single or double-stranded, including modified nucleosides and internucleoside linkages. The composition also involves a cleavable linker for the covalent linkage between the antibody and oligonucleotide.
Furthermore, the patent claims methods of delivering the oligonucleotide complex to a subject, particularly targeting individuals with muscular dystrophy. By administering the complex to the subject, which can be a human, the method aims to utilize the unique structure of the complex to effectively deliver the oligonucleotide. The patent highlights the potential therapeutic applications of this complex in targeted delivery of oligonucleotides for specific medical conditions, emphasizing the importance of the antibody-oligonucleotide linkage in enhancing delivery efficiency and efficacy for therapeutic purposes.
To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
